Radiation plus targeted pills for EGFR lung cancer brain spots
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This Phase 3 study tests whether giving brain radiation early or later, along with almonertinib (a targeted pill), works better for people with EGFR-mutated non-small cell lung cancer that has a small number of brain metastases. It aims to control brain disease while checking safety and effectiveness in a carefully selected group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer confirmed by biopsy (tissue or cell test).
- Your brain MRI shows fewer than 5 brain metastases, with at least one spot 5 mm or larger, and the spots are not too close to the optic nerve or brainstem.
- Your tumor has an EGFR “sensitizing” mutation (either exon 19 deletion or exon 21 L858R).
- You have not used EGFR-targeted drugs or other TKI pills/therapies before.
- You can take pills by mouth and do not have pregnancy or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
This trial tests whether adding nitroglycerin (a medicine that widens blood vessels) to standard whole-brain radiation helps improve treatment for lung cancer that has spread to the brain. It is for people with a specific gene change (EGFR mutation) in their cancer.
This trial tests whether starting focused radiation to brain spots early (called SRS) along with osimertinib works better than taking osimertinib alone. It is for people with lung cancer that has an EGFR mutation and has not yet caused major brain symptoms.
This study tests whether armatinib alone or combined with focused brain radiation (SRT) can control brain metastases from EGFR-mutated non-small cell lung cancer. It aims to improve outcomes for people with few, mostly low-symptom brain spots.
This study uses AI to help doctors decide the best way to use brain radiation for people with EGFR-mutant lung cancer that has spread to the brain. It aims to improve treatment planning and outcomes for those already taking a third-generation targeted therapy.
This Phase 2 trial studies whether giving immunotherapy along with a precise form of brain radiation can control brain metastases from non-small cell lung cancer. It may help by shrinking or stabilizing spots in the brain while your body’s immune system is also activated.
Hear when a new Brain Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.